Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Arch Therapeutics
(OTCQB:ARTH)
Intraday
$1.18
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.18
0
[0.00%]
At close: Apr 24
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Arch Therapeutics Stock (OTC:ARTH)
Arch Therapeutics Stock (OTC: ARTH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, July 27, 2020
HC Wainwright & Co. Maintains Buy on Arch Therapeutics, Lowers Price Target to $1.5
Benzinga Newsdesk
-
Jul 27, 2020, 6:45AM
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
-
Mar 24, 2020, 11:35AM
Monday, October 28, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
-
Oct 28, 2019, 11:12AM
Friday, October 25, 2019
Stocks That Hit 52-Week Lows On Friday
Lisa Levin
-
Oct 25, 2019, 12:49PM
Thursday, October 24, 2019
Stocks That Hit 52-Week Lows On Thursday
Lisa Levin
-
Oct 24, 2019, 10:22AM
Monday, September 23, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
-
Sep 23, 2019, 1:35PM
Wednesday, March 14, 2018
Benzinga's Top Upgrades, Downgrades For March 14, 2018
Benzinga
-
Mar 14, 2018, 9:35AM
IFS Securities Downgrades ARCH THERAPEUTICS INC by Arch Therapeutics, Inc. to Outperform
Benzinga
-
Mar 14, 2018, 7:35AM
Monday, February 13, 2017
Rodman & Renshaw Initiates Coverage On Arch Therapeutics at Buy, Announces $2.50 Target
Benzinga
-
Feb 13, 2017, 7:43AM
Thursday, November 06, 2014
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device
Benzinga
-
Nov 6, 2014, 8:58AM
Monday, September 08, 2014
Arch Therapeutics Announces Positive Preclinical Data of AC5 Surgical Hemostatic Device
Benzinga
-
Sep 8, 2014, 7:58AM
